These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3023205)

  • 1. Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy.
    Grosh WW; Jones HW; Burnett LS; Greco FA
    Gynecol Oncol; 1986 Nov; 25(3):334-9. PubMed ID: 3023205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary.
    Andersen WA; Young DE; Peters WA; Smith EB; Bagley CM; Taylor PT
    Gynecol Oncol; 1989 Mar; 32(3):319-22. PubMed ID: 2537779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.
    Jansen RL; van der Burg ME; Verweij J; Stoter G
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1131-3. PubMed ID: 3115787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 7. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy in advanced forms of carcinoma of the ovary].
    Calciati A; Clerico M; Donadio M; Giaccone G
    Minerva Ginecol; 1984 Apr; 36(4):195-8. PubMed ID: 6431334
    [No Abstract]   [Full Text] [Related]  

  • 10. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
    Levin L; Hryniuk W
    Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
    Carlson JA; Day TG; Botts B; Masterson BJ
    Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
    Greco FA; Johnson DH; Hainsworth JD
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
    Bruckner HW; Cohen CJ; Feuer E; Holland JF
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
    Mäenpää J; Kangas L; Grönroos M
    Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant ovarian germ cell tumors: the experience at the Hospital de la Santa Creu i Sant Pau.
    Germá JR; Izquierdo MA; Seguí MA; Climent MA; Ojeda B; Alonso C
    Gynecol Oncol; 1992 May; 45(2):153-9. PubMed ID: 1375576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cis-diamminedichloroplatinum (II): second line induction chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Barlow JJ; Lele SB; Malfetano JH; McPhee ME
    J Surg Oncol; 1983 Dec; 24(4):329-31. PubMed ID: 6418977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The case for combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    J Clin Oncol; 1985 Nov; 3(11):1445-7. PubMed ID: 3932603
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
    van der Hoop RG; van der Burg ME; ten Bokkel Huinink WW; van Houwelingen C; Neijt JP
    Cancer; 1990 Oct; 66(8):1697-702. PubMed ID: 2119878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
    de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.